Mcmillion Capital Management Inc. cut its position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 2.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,830 shares of the financial services provider’s stock after selling 193 shares during the quarter. Mcmillion Capital Management Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $2,278,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in IBB. FNY Partners Fund LP acquired a new stake in iShares NASDAQ Biotechnology Index during the third quarter worth about $133,000. Wharton Business Group LLC acquired a new stake in iShares NASDAQ Biotechnology Index during the third quarter worth about $208,000. New England Investment & Retirement Group Inc. acquired a new stake in iShares NASDAQ Biotechnology Index during the third quarter worth about $213,000. Leavell Investment Management Inc. acquired a new stake in iShares NASDAQ Biotechnology Index during the third quarter worth about $214,000. Finally, Wayne Hummer Investments L.L.C. acquired a new stake in iShares NASDAQ Biotechnology Index during the second quarter worth about $244,000. 21.09% of the stock is currently owned by institutional investors and hedge funds.

iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $105.17 on Friday. iShares NASDAQ Biotechnology Index has a one year low of $87.97 and a one year high of $114.17.

COPYRIGHT VIOLATION WARNING: “Mcmillion Capital Management Inc. Sells 193 Shares of iShares NASDAQ Biotechnology Index (IBB)” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/12/15/mcmillion-capital-management-inc-sells-193-shares-of-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.